UK markets closed
  • FTSE 100

    6,630.52
    -20.36 (-0.31%)
     
  • FTSE 250

    20,961.31
    -334.92 (-1.57%)
     
  • AIM

    1,163.26
    -10.13 (-0.86%)
     
  • GBP/EUR

    1.1607
    +0.0010 (+0.09%)
     
  • GBP/USD

    1.3834
    -0.0060 (-0.43%)
     
  • BTC-GBP

    35,561.43
    +54.18 (+0.15%)
     
  • CMC Crypto 200

    982.93
    +39.75 (+4.21%)
     
  • S&P 500

    3,841.94
    +73.47 (+1.95%)
     
  • DOW

    31,496.30
    +572.16 (+1.85%)
     
  • CRUDE OIL

    66.28
    +2.45 (+3.84%)
     
  • GOLD FUTURES

    1,698.20
    -2.50 (-0.15%)
     
  • NIKKEI 225

    28,864.32
    -65.78 (-0.23%)
     
  • HANG SENG

    29,098.29
    -138.50 (-0.47%)
     
  • DAX

    13,920.69
    -135.65 (-0.97%)
     
  • CAC 40

    5,782.65
    -48.00 (-0.82%)
     

Asia-PacificPharmaceutical Contract Research Organization (CRO) Markets, 2019-2020 & 2030: Pre-clinical Development, Phase I Trials-Phase IV Trials, Laboratory, Consulting, Data Management

Research and Markets
·4-min read

Dublin, Feb. 12, 2021 (GLOBE NEWSWIRE) -- The "Asia-Pacific Pharmaceutical Contract Research Organization (CRO) Market 2020-2030 by Service, Therapeutic Application, End User, and Country: Trend Forecast and Growth Opportunity" report has been added to ResearchAndMarkets.com's offering.

Asia-Pacific's pharmaceutical CRO market will grow by 9.6% annually with a total addressable market cap of $238.7 billion over 2020-2030 owing to the rising incidence of disease, rising healthcare expenditures, increasing dependence on contract research organizations due to improved efficiency and productivity.

Highlighted with 33 tables and 44 figures, this report is based on comprehensive research of the entire Asia-Pacific pharmaceutical CRO market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies of the period 2015-2019 and provides a forecast from 2020 till 2030 with 2019 as the base year.

The trend and outlook of Asia-Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia-Pacific pharmaceutical CRO market in every aspect of the classification from perspectives of Service, Therapeutic Application, End User, and Country.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.

Specifically, potential risks associated with investing in Asia-Pacific pharmaceutical CRO market are assayed quantitatively and qualitatively through a Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.

Key Players

  • Charles River Laboratories

  • CMIC Co. Ltd

  • Covance Inc.

  • Hangzhou Tigermed Consulting Co Ltd

  • ICON Plc

  • IQVIA Holdings Inc.

  • LSK Asia-Pacific Pharma Service Co Ltd

  • Novotech Pty Ltd

  • PAREXEL International Corporation

  • Pharmaceutical Product Development LLC (PPD)

  • PRA Health Sciences Inc.

  • Quanticate Ltd

  • Samsung Bioepis Co. Ltd

  • SGS SA (SGS Life Sciences)

  • Syneos Health Inc.

  • WuXi AppTec Inc.


Key Topics Covered:

1 Introduction
1.1 Industry Definition and Research Scope
1.1.1 Industry Definition
1.1.2 Research Scope
1.2 Research Methodology
1.2.1 Overview of Market Research Methodology
1.2.2 Market Assumption
1.2.3 Secondary Data
1.2.4 Primary Data
1.2.5 Data Filtration and Model Design
1.2.6 Market Size/Share Estimation
1.2.7 Research Limitations
1.3 Executive Summary

2 Market Overview and Dynamics
2.1 Market Size and Forecast
2.1.1 Impact of COVID-19 on World Economy
2.1.2 Impact of COVID-19 on the Market
2.2 Major Growth Drivers
2.3 Market Restraints and Challenges
2.4 Emerging Opportunities and Market Trends
2.5 Porter's Fiver Forces Analysis

3 Segmentation of Asia-Pacific Market by Service
3.1 Market Overview by Service
3.2 CRO for Pre-clinical Development
3.3 CRO for Phase I Trials
3.4 CRO for Phase II Trials
3.5 CRO for Phase III Trials
3.6 CRO for Phase IV Trials
3.7 Laboratory Services
3.8 Consulting Services
3.9 Data Management Services

4 Segmentation of Asia-Pacific Market by Therapeutic Application
4.1 Market Overview by Therapeutic Application
4.2 Infectious Diseases
4.3 Oncology
4.4 Metabolic Disorders
4.5 Cardiovascular Disorders
4.6 Central Nervous System
4.7 Respiratory Disorders
4.8 Gastrointestinal Disorders
4.9 Other Therapeutic Applications

5 Segmentation of Asia-Pacific Market by End User
5.1 Market Overview by End User
5.2 Pharmaceutical & Biopharmaceutical Companies
5.3 Medical Device Companies
5.4 Academic Institutes

6 Asia-Pacific Market 2019-2030 by Country
6.1 Overview of Asia-Pacific Market
6.2 Japan
6.3 China
6.4 Australia
6.5 India
6.6 South Korea
6.7 Rest of APAC Region

7 Competitive Landscape
7.1 Overview of Key Vendors
7.2 New Product Launch, Partnership, Investment, and M&A
7.3 Company Profiles

8 Investing in Asia-Pacific Market: Risk Assessment and Management
8.1 Risk Evaluation of Asia-Pacific Market
8.2 Critical Success Factors (CSFs)

For more information about this report visit https://www.researchandmarkets.com/r/9ao42w

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900